Hospital San Jose

Hospital San Jose’s pediatric unit is advancing care for children with achondroplasia and related growth disorders, testing innovative medicines aimed at increasing height potential. The trials also explore treatments for hypochondroplasia to improve stature and quality of life.

• Evaluation of growth‑enhancing agents
• Assessment of safety and tolerability in young patients
• Comparison of novel therapies against standard care

These efforts position the site as a leading center for rare skeletal disease research in Europe.

Focused on pediatric skeletal dysplasia, the research at the hospital investigates how new compounds can support bone development in children with achondroplasia. The goal is to provide effective solutions for short stature linked to musculoskeletal abnormalities.

• Bone lengthening strategies
• Functional outcome measurements
• Longitudinal growth tracking

Findings are expected to inform clinical guidelines for managing musculoskeletal conditions in children.

The program examines the genetic mechanisms behind dwarfing conditions, targeting the FGFR3 pathway with precision medicines. By linking genotype to therapeutic response, researchers aim to personalize treatment for affected youths.

• Molecular inhibition studies
• Genotype‑phenotype correlation analysis
• Biomarker identification for treatment response

Collaboration with international genetics labs enhances the scientific impact of the work conducted at Hospital San Jose.